JUXTAPID 20 MG — DIN 02420384
LOMITAPIDE (LOMITAPIDE MESYLATE) : 20 MG · CHIESI FARMACEUTICI S.P.A. · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is JUXTAPID?
JUXTAPID 20 MG contains LOMITAPIDE (LOMITAPIDE MESYLATE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02420384, held by CHIESI FARMACEUTICI S.P.A., supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Feb-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JUXTAPID used for?
Adjunct to low-fat diet and other lipid-lowering drugs to reduce LDL-C in adult patients with homozygous familial hypercholesterolemia (HoFH).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Lomitapide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Lomitapide — 3 DINs, of which 3 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| CHIESI FARMACEUTICI S.P.A. | 3 | 3 | JUXTAPID | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 28 capsules. |
| Storage | Not explicitly detailed in provided text (section 11 header present but content truncated), though typically room temperature. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Lomitapide |
|---|---|
| ATC code | C10AX12 |
| AHFS class | 84:80.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02420384 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2420384 |
| Brand name | JUXTAPID |
| Generic / active ingredient | LOMITAPIDE (LOMITAPIDE MESYLATE) : 20 MG |
| Market authorization holder | CHIESI FARMACEUTICI S.P.A. |
| Health Canada schedule | Prescription |
| ATC code | C10AX12 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10AX |
| Current status | MARKETED |
| Status date | 23-Feb-2024 |
| Original market date | 2014-04-24 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Initial 5 mg daily. Titrate to 10, 20, 40, up to max 60 mg at min 4-week intervals based on safety/tolerability. Take without food, at least 2 hours after evening meal. Swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Moderate/severe hepatic impairment; chronic bowel disease; strong/moderate CYP3A4 inhibitors; pregnancy; concomitant simvastatin >20mg daily; hypersensitivity; rare hereditary galactose intolerance.
Warnings and precautions
Risk of hepatotoxicity (elevated transaminases, hepatic steatosis); severe diarrhea and dehydration; potential for birth defects; avoid grapefruit juice and limit alcohol.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JUXTAPID | 5 MG | CAPSULE | CHIESI FARMACEUTICI S.P.A. | MARKETED | 02420341 |
| JUXTAPID | 10 MG | CAPSULE | CHIESI FARMACEUTICI S.P.A. | MARKETED | 02420376 |
2 · Same class — other molecules in ATC C10AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ezetimibe | ACH-EZETIMIBE · ACT EZETIMIBE · AG-EZETIMIBE · APO-EZETIMIBE · +19 more | 26 | 18 | Yes |
| Alirocumab | PRALUENT | 5 | 3 | Yes |
| Lomitapide | JUXTAPID | 3 | 3 | Yes |
| Omega-3-Triglycerides Incl. Other Esters And Acids | FLEX 500 · HERBALIFELINE · OMEGA-3 · VASCEPA | 4 | 1 | Yes |
| Evolocumab | REPATHA | 2 | 1 | Yes |
| Inclisiran | LEQVIO | 1 | 1 | Yes |
| Evinacumab | EVKEEZA | 1 | 1 | Yes |
| Dextrothyroxine | CHOLOXIN - TAB 4MG · CHOLOXIN TAB 2MG · CHOLOXIN TABLET 4MG | 4 | 0 | Not in Canada |
| Omega-3-Triglycerides, Combinations | OMEGA-3 FACTORS WITH VITAMIN E | 1 | 0 | Not in Canada |
| Probucol | LORELCO | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C10AA | Atorvastatin · Cerivastatin · Fluvastatin · Lovastatin · Pravastatin · +2 more | 759 | 286 |
| C10AB | Bezafibrate · Clofibrate · Fenofibrate · Gemfibrozil | 87 | 13 |
| C10AC | Colesevelam · Colestipol · Colestyramine | 29 | 6 |
| C10AD | Nicotinic Acid | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.